FDA has approved Camzyos (mavacamten) capsules to treat\u202fadults with symptomatic New York Heart Association (NYHA)External Link Disclaimer class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve exercise capacity and symptoms. oHCM is a rare disease that occurs when the heart muscle thickens, mostly in the septum (the heart wall that separates its right and left sides) and obstructs blood flow from the heart to the rest of the body.\u00a0Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.<\/p>\n
CAMZYOS\u00ae (mavacamten) capsules for oral use Initial U.S. Approval: 2022<\/strong><\/p>\n CAMZYOS (mavacamten) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n Note:<\/strong><\/em> Camzyos is used\u00a0to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM)<\/b>. Hypertrophic cardiomyopathy (HCM) is a condition where the walls of the heart chamber (left ventricle) contract harder and become thicker than normal.<\/p>\nIs CAMZYOS (mavacamten) available in India?<\/h4>\n
How to get CAMZYOS capsules delivered in India?<\/h4>\n
Who can help source CAMZYOS capsules in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"CAMZYOS (mavacamten) \u2013 Hypertrophic cardiomyopathy (HCM) therapy in India<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n CAMZYOS<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n mavacamten<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Capsules: 2.5 mg, 5 mg, 10 mg, and 15 mg<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Bristol-Myers Squibb<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n